Social Media Ideas for Ardx

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord.

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

argenx SE (ARGX) Forte Biosciences, Inc. - M&A Call - Slideshow

Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies

ADARx has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical trials of a range of next-gen small interfering RNA medicines.

Archer Limited (ARHVF) Q2 2026 Earnings Call Prepared Remarks Transcript

Axsome Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

AMG River Road Dividend All Cap Value Fund Q2 2026 Commentary

Argenx jumps on Phase 3 data for blockbuster Vyvgart

The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments. 

Syndax

Syndax Anonymous (not verified) Sun, 07/19/2026 - 15:19 field_thread_url https://cafepharma.com/boards/threads/syndax.695213/ board name...

Recursion (RXRX) Q2 2026 Earnings Call Transcript

AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.

<![CDATA[argenx Acquires Forte Biosciences for $2.2 Billion]]>

argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?

Array Technologies, Inc. (ARRY) Affordable Wire Management, LLC, - M&A Call - Slideshow

Antero Resources Corporation (AR) Q2 2026 Earnings Call Transcript

ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy

argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go

Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.

Artisan International Value Fund Q2 2026 Commentary

Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between Marc...

ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript